老年精神分裂症合并肺炎临床分析

目的：通过对精神分裂症合并肺炎患者和老年肺炎患者进行对照观察分析，探索老年精神分裂症合并肺炎的临床特点，为临床诊治提供资料。方法：对35例CCMD-2-R精神分裂症合并肺部感染的患者及35例同期老年肺炎患者对照分析。结果：发现老年精神分裂症合并肺炎患者与老年肺炎患者在神经精神症状和消化系统症状方面差异有显著性。结论：对老年精神分裂症合并肺炎患者更要细致观察，精心护理，早发现、早诊断、早治疗，以降低其死亡率。     

老年牙周组织疾病216例证候分析

目的 探讨老年牙周组织疾病的证候特点。方法 对 1998 年 1 月-2003 年 12 月门诊接诊的 216 例老年牙周组织疾病进行回顾性分析。结果 阴虚火旺型 124 例(57.4%),气血不足型 51 例(23.6%),胃火炽盛型 16 例(7.5%),气滞血瘀型 14 例(6.4%),痰湿阻络型 11 例(5.1%)。结论 老年牙周组织疾病证候表现以虚为主、虚中夹实,阴虚火旺型和气血不足型是其主要证候类型。     

老年人慢性腰腿痛病因分析及临床治疗

目的探讨老年慢性腰腿痛的常见病因及其治疗。方法选择1997年1月至2000年12月间162例老年慢性腰腿痛患者，椎间盘突出92例（其中合并腰椎管狭窄者63例），单纯腰椎管狭窄10例，腰椎峡部裂或滑脱者37例，骨质疏松者23例。结果47例患者经保守治疗后出院，但其中18例症状复发。115例患者行手术治疗，其中椎板间扩大开窗或半椎板切除髓核摘除75例，全椎板切除髓核摘除9例，单纯峡部植骨术8例，脊柱内固定者23例。97例手术患者获得随访，平均18个月，症状消失或明显缓解者65例，残留部分症状者29例，无改善者3例。结论脊柱退行性变是导致老年人慢性腰腿痛的主要原因，以腰椎间盘突出和椎管狭窄为主，治疗上先予保守治疗，效果差时可积极手术治疗。     

奥沙利铂为主的化疗方案治疗老年非小细胞肺癌疗效观察

目的 观察以奥沙利铂(O-LHP)为主的联合化疗方案对老年非小细胞肺癌的疗效和安全性。方法23例老年非小细胞肺癌患者接受治疗，化疗方案采用O-LHP VP-16(或口服威克)，每个病例至少化疗2周期。结果完全缓解1例，部分缓解7例，有效率为34．8％；主要毒副反应为白细胞下降和神经毒性，患者可以耐受。结论以奥沙利铂为主的联合化疗方案对老年非小细胞肺癌的治疗安全有效。     

心理干预对社区老年抑郁病人的影响

[目的 ]探讨心理干预对社区老年抑郁病人的影响。 [方法 ]采用对照研究的方法 ,按区域用老年抑郁量表(GDS)将筛选出的符合标准的老年抑郁病人分为干预组及对照组 ,对干预组病人进行 3个月的心理干预 ,3个月后两组进行GDS评分及抑郁障碍缓解率的比较分析。 [结果 ]干预前两组GDS分数比较无统计学意义 ,3个月后干预组GDS得分显著低于对照组 ;干预后干预组的抑郁障碍缓解率显著高于对照组。 [结论 ]心理干预可以显著减轻老年抑郁病人的抑郁症状 ,提高抑郁病人的缓解率。     

Heart Transplantation in a 68-Year-Old Patient with Senile Systemic Amyloidosis

Senile systemic amyloidosis (SSA) results from deposition, predominantly in the heart, of amyloid fibrils derived from wild-type transthyretin (T TR) molecules. Cardiac autopsies indicate that SSA progressively increases in subjects 80 years of age and older. However, only a few cases of patients with SSA and cardiac failure have been recognized by cardiac biopsies during life. Here, we report a case of heart transplantation in a 68-year-old male patient with SSA. After cardiopulmonary resuscitation in October 1998, he underwent complete evaluation. Myocardial biopsies revealed the presence of amyloid deposition. Immunohistochemical staining of the amyloid indicated T TR. Genomic DNA analysis of the T TR exons did not result in any identification of a mutation. In 2001, heart transplantation was performed because progressive heart failure occurred. At the 1-year follow-up, no amyloid deposits were found in the donor heart. At the 2-year follow-up, the patient's physical and mental health was excellent. We conclude that heart transplantation can be an effective treatment in progressive heart failure due to SSA.     

The heat shock/oxidative stress connection

Involvement of free-radical oxidations in the aging process has been a topic of interest since Harman's original contribution. Because of the close association between aging and Alzheimer disease (AD) and the qualitative similarity in the neuropathology of both conditions, it has been proposed by many investigators that oxidative stress may be important in AD. If such modality of injury was indeed involved, one should expect to find markers of oxidation and heat shock (since free radicals are key mediators of heat-shock induction) in brains of patients with AD. In fact, several studies documented abnormal expression of antioxidant enzymes and heat-shock proteins (HSP) along with other markers of oxidation in AD brains. We showed that abnormally expressed antioxidant enzymes are topographically associated with senile plaques and neurofibrillary tangles, and that the activity of these enzymes is (contrary to what one would expect) markedly reduced. These findings have recently been confirmed by other investigators. Despite a large amount of evidence that suggests an association between oxidative stress and the pathogenesis of AD, it is not yet known whether oxidative stress is a cause or consequence of the disorder. Future research efforts regarding the oxidative stress hypothesis of AD should include attempts, at generating AD pathology by oxidative means in laboratory animals, determining the role and integrity of the heat-shock response in AD, as well as that of various antioxidant systems, growth factors, and hormones with antioxidant and neuroprotective properties.     

Single-dose and steady-state pharmacokinetics of sabeluzole in senile dementia of Alzheimer type patients

Summary The single- and repeated-dose pharmacokinetics of sabeluzole have been determined in six elderly patients with [senile] dementia of the Alzheimer type.After a single oral dose of 10 mg sabeluzole, the peak plasma concentration was attained at 1 to 4 h; it averaged 42 ng·ml^–1. On repeated dosing (10 mg b. d.), steady-state was virtually attained after 3 days of treatment. Steadystate mean trough and peak plasma concentrations fluctuated between 53 and 94 ng·ml^–1. The mean terminal half-life after a single dose and at steady-state was of the order of 33 h.Sabeluzole was well tolerated and at the end of treatment, no systematic changes in blood haematology, biochemistry or urinalysis were seen.     

The neurochemistry of Alzheimer's disease

Our knowledge of the neurochemical pathology of AD has increased immensely the last years. Although it is now clear that mutations in the APP gene can cause some rare hereditary forms of AD, and that ApoE4 is a prominent risk factor for AD, we at present know little about the underlying cause of AD in the general population and the biochemical mechanisms by which the apolipoprotein E4 isoform affects AD pathogenesis. It is hoped that the near future will see a resolution of the current controversies in AD research, including: 1) whether APP mutations cause Alzheimer's disease by affecting Aβ deposition or the function of APP itself; 2) whether abnormal phosphorylation of tau is a central pathogenetic event, or whether it occurs as epiphenomena that reflect general neurodegeneration in a variety of disease processes; 3) Whether Aβ deposition in the brain is the central event in AD or whether it occurs as epiphenomena in a variety of brain disorders such as head trauma; and 4) whether altered tau phosphorylation occurs secondary to Aβ deposition or vice versa, and what the link is (if any) between the two processes.     

解毒降浊、益气活瘀是治疗老年缺血性卒中的主要治则

老年缺血性卒中在病因病机、治疗方法等方面迥异于老年前期缺血性卒中患者。根据老年人的生理病理特点结合临床实际，认为正虚血瘀为本，浊毒内蕴为标，毒损脑络为老年脑缺血损伤的终结；正虚血瘀、浊毒内蕴是老年脑缺血损伤的根本原因；解毒降浊、益气活血是治疗老年缺血性卒中的重要方法之一。